Adam Feuerstein

TheStreet.com Senior Columnist

Before joining TheStreet.com in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
« Back
Page 1 of 429
Article

FDA Advisory Panels: A Coin Flip

By Adam Feuerstein

FDA advisory panels in 2010 are voting against new drugs more than any other time since 2007.

10:25AM 09/02/10

Article

Somaxon: Readers Respond (Angrily)

By Adam Feuerstein

Most, but not all, readers unhappy with Adam Feuerstein's skeptical take on Somaxon and its soon-to-be-launched insomnia drug Silenor.

07:07AM 09/02/10

Article

Orexigen, Takeda Tie Knot on Obesity Drug

By Adam Feuerstein

Orexigen gets $50 million upfront for North American rights to its experimental obesity drug Contrave

06:50AM 09/02/10

Article

Biotech Calendar: Key Dates for September

By Adam Feuerstein

Here's a list of September's potentially stock-moving biotech events

07:00AM 09/01/10

Article

Genzyme Sale Inevitable, Buysiders Say

By Adam Feuerstein

Sooner or later Sanofi-Aventis will cough up more cash and buy Genzyme, predicts a group of healthcare investors.

12:33AM 09/01/10

Article

Dendreon: Medicare Coverage Fears Allayed

By Adam Feuerstein

Medicare sets a Nov. 17 meeting to discuss Dendreon's Provenge, but the focus will be on which patients should get the prostate cancer vaccine, not whether to cover it at all.

08:10PM 08/31/10

Article

Dendreon Gets Date for Medicare Meeting

By Adam Feuerstein

Medicare will hold a meeting Nov. 17 to discuss use of Dendreon's prostate cancer vaccine Provenge.

05:05PM 08/31/10

Article

Somaxon: P&G Won't Wake Up Silenor Sales

By Adam Feuerstein

Somaxon lands a big-name marketing partner for its sleep drug Silenor, but competition from cheap generics remains a challenging impediment.

12:31PM 08/31/10

Article

21 Drugs Facing FDA Approval Decisions

By Adam Feuerstein

Here is the updated list of drugs facing FDA approval decisions.

08:21AM 08/31/10

Article

ImmunoGen Wounds Are Not Fatal

By Adam Feuerstein

The approval delay for the breast cancer drug TDM-1 is a clear setback, but the drug works and patient investors will still be rewarded.

01:56PM 08/30/10

« Back
Page 1 of 429

TheStreet Premium Services

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Now any level of investor can trade right alongside a Wall Street pro — and enjoy 24/7 access to his portfolio! Learn More
RealMoney Silver
RealMoney Silver:
Get Doug Kass's exclusive trading diary + 5 of TheStreet's top premium services including Action Alerts PLUS and RealMoney — all on one streamlined page. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Bryan Ashenberg
Breakout Stocks:
Find tomorrow's household names today. Bryan Ashenberg finds hidden gems in exciting up-and-coming markets that he believes are ready to break out! Learn More
Dow Jones S&P 500 NASDAQ 10-Year Note
10,280.75 1,082.62 2,187.37 26.21
Oil *
75.41
UP
11.28
UP
2.33
UP
10.53
UP
0.39
10 Yr
2.62%
SPDR Gold
122.04
+0.11%
+0.22%
+0.48%
+1.51%
Data delayed 20 minutes

Latest Trade Alerts

See all

Brokerage Partners

After the Bell

Before the Bell

Booyah! Newsletter

ETF Daily

Midday Bell

TSC Top Ten Stories Newsletter

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet